The U.S FDA approved ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic administered by a healthcare professional with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. The product is manufactured by Dublin, Ireland-based Alkermes Plc. Alkermes is preparing to launch ARISTADA immediately.
Schizophrenia is a chronic, severe and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as disorganized thinking. An estimated 2.4 million American adults have schizophrenia, with men and women affected equally.